+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Renal Cancer Drugs Market 2019-2025

  • PDF Icon


  • June 2020
  • Region: Global
  • Orion Market Research Private Limited
  • ID: 5129670
Global Renal Cancer Drugs Market Size, Share & Trends Analysis Report By Cancer Type (Renal Cancer Carcinoma, Clear Cell Renal Cell Carcinoma, Non-Clear Renal Cell Carcinoma, and Others), By Drug Class (Angiogenesis Inhibitors, Monoclonal Antibodies, mTOR Inhibitors, and Cytokine Immunotherapy (IL-2)), By Therapeutic Class (Targeted Therapy and Immunotherapy, and Chemotherapy), and Forecast 2019-2025.

Market Outlook
The global renal cancer drug market is projected to grow significantly during the forecast period. The primary factors that drive the growth of the market include increased incidences of renal cancer along with the increased awareness regarding renal cancer amongst the peoples. Further, according to the American Cancer Society, there were around 74,000 new cases of kidney cancer in 2019. Kidney and renal pelvis cancer overall accounted for 4.2% of all new cancer cases in the US alone. Amongst these cancer cases, around 40% of patients die due to the complications. However, higher prices of the drug may hamper market growth. Besides, footprints of the key players along with the rising geriatric population are creating scope for the market growth.

The global renal cancer drug market is segmented on the basis of cancer type, drug class, and therapeutic class. Based on the cancer type, the market is segmented into renal cancer carcinoma, clear cell renal cell carcinoma, non-clear renal cell carcinoma, and others. Renal cancer carcinoma is anticipated to hold a significant share in the market. Based on the drug class, the market has been segmented into angiogenesis inhibitors, monoclonal antibodies, mTOR inhibitors, and cytokine immunotherapy (IL-2). Based on the therapeutic class, the market is segmented into targeted therapy, immunotherapy, and chemotherapy. Immunotherapy is estimated to hold a significant share in the market.

Geographically, the study of the global renal cancer drug market report covers the analysis of four major regions including North America (the US and Canada), Europe (UK, Germany, Italy, Spain, France, and Rest of Europe), Asia-Pacific (China, Japan, India, and the Rest of Asia-Pacific), and the Rest of the World. Asia-Pacific is estimated to exhibit a significant growth rate in the global renal cancer drug market during the forecast period. The increasing geriatric population in the region drives the growth of the market. In addition, improving healthcare infrastructure further gives a boost to the regional growth of the market.

Further, Pfizer, Inc., Bayer AG, Bristol Myers Squibb Co., Amgen Inc., GlaxoSmithKline Plc, Prometheus Laboratories Inc., Rosetta Genomics Ltd., Sysmex Corp., and others are some of the prominent players operating in the global renal cancer drugs market. New product launches & developments, partnerships, agreements, and acquisitions are some of the growth strategies adopted by the players to sustain in the highly competitive market.

Research Methodology

The market study of the global renal cancer drug market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook.

In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. The analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity of the reports.

Secondary sources include:
  • Financial reports of companies involved in the market
  • Whitepapers, research-papers, and news blogs
  • Company websites and their product catalog
The report is intended for pharmaceutical companies, drug manufacturers, active pharmaceutical ingredient manufacturers, contract manufacturers, healthcare organizations, industry associations and experts, research institutes, government organizations, regulatory bodies, and other market participants for overall market analysis and competitive analysis. The report provides an in-depth analysis of the market size and growth opportunities. The report will serve as a source for 360-degree analysis of the market thoroughly delivering insights into the market for making better business decisions.

Market Segmentation:

1. Global Renal Cancer Drug Market Research and Analysis by Cancer Type
2. Global Renal Cancer Drug Market Research and Analysis by Drug Class
3. Global Renal Cancer Drug Market Research and Analysis by Therapeutic Class

The Report covers:
  • Comprehensive research methodology of the global renal cancer drug market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global renal cancer drug market.
  • Insights about market determinants which are stimulating the global renal cancer drug market.
  • Detailed and extensive market segments with regional distribution of forecast revenues.
  • Extensive profiles and recent developments of the market players.

Table of Contents

1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations
3. Competitive Landscape
3.1. Key Company Analysis
3.1.1. Bayer AG Overview Financial Analysis SWOT Analysis Recent Developments
3.1.2. Pfizer Inc. Overview Financial Analysis SWOT Analysis Recent Developments
3.1.3. Novartis InternationalAG Overview Financial Analysis SWOT Analysis Recent Developments
3.1.4. Bristol-Myers Squibb Co. Overview Financial Analysis SWOT Analysis Recent Developments
3.2. Key Strategy Analysis
4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities
5. Market Segmentation
5.1. Global Renal Cancer Drugs Market by Cancer Type
5.1.1. Renal Cancer Carcinoma
5.1.2. Clear Cell Renal Cell Carcinoma
5.1.3. Non-Clear Renal Cell Carcinoma
5.1.4. Others
5.2. Global Renal Cancer Drugs Market by Drug Class
5.2.1. Angiogenesis Inhibitors
5.2.2. Monoclonal Antibodies
5.2.3. mTOR Inhibitors
5.2.4. Cytokine Immunotherapy (IL-2)
5.3. Global Renal Cancer Drugs Market by Therapeutic Class
5.3.1. Targeted Therapy
5.3.2. Immunotherapy
5.3.3. Chemotherapy
6. Regional Analysis
6.1. North America
6.1.1. United States
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Italy
6.2.4. Spain
6.2.5. France
6.2.6. Rest of Europe
6.3. Asia-Pacific
6.3.1. China
6.3.2. India
6.3.3. Japan
6.3.4. Rest of Asia-Pacific
6.4. Rest of the World
7. Company Profiles
7.1. Active Biotech AB
7.2. Amgen Inc.
7.3. Aravive, Inc.
7.4. Argos Therapeutics Inc.
7.5. Bayer AG
7.6. Bristol Myers Squibb Co.
7.7. Cipla Ltd.
7.8. Eisai Co., Ltd.
7.9. Exelixis, Inc.
7.10. Genentech, Inc.
7.11. GlaxoSmithKline Plc
7.12. Myriad Genetics Inc.
7.13. NanoString Technologies Inc.
7.14. NeoGenomics Laboratories Inc.
7.15. Novartis International AG
7.16. Pfizer, Inc
7.17. Prometheus Laboratories Inc.
7.18. Rosetta Genomics Ltd.
7.19. Sysmex Corp.

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Active Biotech AB
  • Amgen Inc.
  • Aravive, Inc.
  • Argos Therapeutics Inc.
  • Bayer AG
  • Bristol Myers Squibb Co.
  • Cipla Ltd.
  • Eisai Co., Ltd.
  • Exelixis, Inc.
  • Genentech, Inc.
  • GlaxoSmithKline Plc
  • Myriad Genetics Inc.
  • NanoString Technologies Inc.
  • NeoGenomics Laboratories Inc.
  • Novartis International AG
  • Pfizer, Inc
  • Prometheus Laboratories Inc.
  • Rosetta Genomics Ltd.
  • Sysmex Corp.